Ceftobiprole and ampicillin increase daptomycin susceptibility of daptomycin-susceptible and -resistant vre

Journal of Antimicrobial Chemotherapy

Volumn 70, Issue 2, 2015, Pages 489-493

  Werth, Brian J ^a,e   Barber, Katie E ^a   Tran, Kieu Nhi T ^a   Nonejuie, P ^b   Sakoulas, G ^c   Pogliano, J ^b   Rybak, Michael J ^a,d  

^a WAYNE STATE UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Combination therapy; Synergy; lactams

Indexed keywords

AMPICILLIN; CEFTOBIPROLE; DAPTOMYCIN; CEPHALOSPORIN DERIVATIVE;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; BINDING AFFINITY; BROTH DILUTION; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENTIATION; IN VITRO STUDY; NONHUMAN; VANCOMYCIN RESISTANT ENTEROCOCCUS; VANCOMYCIN RESISTANT ENTEROCOCCUS FAECALIS; VANCOMYCIN RESISTANT ENTEROCOCCUS FAECIUM; DOSE RESPONSE; DRUG EFFECTS; ENTEROCOCCUS; GENETICS; HUMAN; MICROBIAL SENSITIVITY TEST;

AMPICILLIN; CEPHALOSPORINS; DAPTOMYCIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; ENTEROCOCCUS; HUMANS; MICROBIAL SENSITIVITY TESTS; VANCOMYCIN RESISTANCE;

EID: 84922473318     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dku386     Document Type: Article

References (15)

1. Arias CA, Contreras GA, Murray BE. Management of multidrug-resistant enterococcal infections. Clin Microbiol Infect 2010; 16: 555-62.
2. Boucher HW, Talbot GH, Bradley JS et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 2009; 48: 1-12.
3. Boucher HW, Talbot GH, Benjamin DK Jr et al. 10 × '20 Progress-development of new drugs active against gram-negative bacilli: an update from the Infectious Diseases Society of America. Clin Infect Dis 2013; 56: 1685-94.
4. Sakoulas G, Bayer AS, Pogliano J et al. Ampicillin enhances daptomycinand cationic host defense peptide-mediated killing of ampicillin- and vancomycin-resistant Enterococcus faecium. Antimicrob Agents Chemother 2012; 56: 838-44.
5. Sakoulas G, Rose W, Nonejuie P et al. Ceftaroline restores daptomycin activity against daptomycin-nonsusceptible vancomycin-resistant Enterococcus faecium. Antimicrob Agents Chemother 2014; 58: 1494-500.
6. Henry X, Amoroso A, Coyette J et al. Interaction of ceftobiprole with the low-affinity PBP 5 of Enterococcus faecium. Antimicrob Agents Chemother 2010; 54: 953-5.
7. Deshpande LM, Jones RN. Bactericidal activity and synergy studies of BAL9141, a novel pyrrolidinone-3-ylidenemethyl cephem, tested against streptococci, enterococci and methicillin-resistant staphylococci. Clin Microbiol Infect 2003; 9: 1120-4.
8. Arias CA, Singh KV, Panesso D et al. Time-kill and synergism studies of ceftobiprole against Enterococcus faecalis, including β-lactamaseproducing and vancomycin-resistant isolates. Antimicrob Agents Chemother 2007; 51: 2043-7.
9. Vidaillac C, Leonard SN, Rybak MJ. In vitro activity of ceftaroline against methicillin-resistant Staphylococcus aureus and heterogeneous vancomycin-intermediate S. aureus in a hollow fiber model. Antimicrob Agents Chemother 2009; 53: 4712-7.
10. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Twenty-second Informational Supplement M100-S22. CLSI, Wayne, PA, USA, 2012.
11. Leonard SN, Cheung CM, Rybak MJ. Activities of ceftobiprole, linezolid, vancomycin, and daptomycin against community-associated and hospital-associated methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2008; 52: 2974-6.
12. Benvenuto M, Benziger DP, Yankelev S et al. Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers. Antimicrob Agents Chemother 2006; 50: 3245-9.
13. Pogliano J, Osborne N, Sharp MD et al. A vital stain for studying membrane dynamics in bacteria: a novel mechanism controlling septation during Bacillus subtilis sporulation. Mol Microbiol 1999; 31: 1149-59.
14. Dhand A, Bayer AS, Pogliano J et al. Use of antistaphylococcal β-lactams to increase daptomycin activity in eradicating persistent bacteremia due to methicillin-resistant Staphylococcus aureus: role of enhanced daptomycin binding. Clin Infect Dis 2011; 53: 158-63.
15. Arbeloa A, Segal H, Hugonnet JE et al. Role of class A penicillin-binding proteins in PBP5-mediated β-lactam resistance in Enterococcus faecalis. J Bacteriol 2004; 186: 1221-8.